Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults

NCT06861101 | Completed Phase 2

• 1 other identifier: JT002-001-II-SAR
• Study Type: interventional
• Target: 370
• Locations: 1 country
• Sites: 44

Brief Summary

The study included three phases: the treatment introduction period (4-7 days before randomization), the treatment period (14 days after randomization) and the follow-up period (7 days after the last dose). Eligible participants in this study entered the 4-7 day treatment introduction period. After completing the treatment introduction period, patients who did not meet the random exclusion criteria of this study were randomly assigned to one of the 4 dose cohorts in a 1:1:1:1 ratio, with 80 patients planned to be enrolled in each cohort, and then randomly assigned to receive the investigational product or placebo in the cohort at a 4:1 ratio, for a total of 320 patients. Participants were stratified by prior Drug therapy for Rhinitis allergic. Ultimately, the proportion of patients receiving 200 μg BID, 400 μg BID, 400 μg QD, 800 μg QD and placebo was 1:1:1:1:1 (64 patients in each group).

Conditions

Seasonal Allergic Rhinitis

Outcome Measures

Primary Outcomes (1)

• rTNSS

  Change from baseline in mean (AM+PM) rTNSS (reactive nasal symptom total score)

  During the 14-day treatment period

Secondary Outcomes (19)

• iTNSS

  During the 14-day treatment period

• rTOSS

  During the 14-day treatment period

• iTOSS

  During the 14-day treatment period

• AM rTNSS

  During the 14-day treatment period

• AM iTNSS

  During the 14-day treatment period

Other Outcomes (3)

• PD(IgE)

  Through study completion,Estimated 22 days

• PD(IFN-α)

  Through study completion,Estimated 22 days

• PD( CXCL10)

  Through study completion,Estimated 22 days

Study Arms (2)

JT002

EXPERIMENTAL

200 μg BID, 400 μg BID, 400 μg QD, 800 μg QD

Drug: JT002 Nasal spray

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

JT002 Nasal spray DRUG

200 μg BID, 400 μg BID, 400 μg QD, 800 μg QD, 64 patients per cohort, total 256 patients for treatment 14 days

JT002

Placebo DRUG

Total 64 patients for treatment 14 days

Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The participant voluntarily signed the informed consent form before the start of any study-related procedures, was able to communicate smoothly with the investigator, was able to correctly use the device for the study drug, understood and was willing to strictly comply with this clinical study protocol, study procedures, visit schedule, treatment plan, Laboratory test and other study requirements specified in the protocol.
• Male and female patients aged 18 to 75 years on screening day (inclusive of the cutoff value).
• Patients with seasonal allergic rhinitis, confirmed prior history for ≥ 1 year (including the main complaints) at screening, based on the diagnosis criteria referred to the 2022 Revised Edition of the Guidelines for Diagnosis and Treatment of Allergic Rhinitis in China published by the Chinese Medical Association Head and Neck Surgery Branch of Otolaryngology Head and Neck Surgery, confirmed positive results for one or more seasonal allergens in allergen tests (e.g., pollen, fungi, etc.), positive results in skin prick test or serum specific Immunoglobulins (IgE) for any allergen, positive nasal challenge test (acceptable results within the past 12 months).
• The environment of seasonal allergy exposure for the patient does not change during the study.
• Total score of reflective nasal symptoms on screening day (rTNSS) ≥ 6 points (maximal score 12 points), and nasal congestion ≥ 2 points.
• Female participants of childbearing potential must be willing to use highly effective contraceptive methods during the study period until 1 month after the last dose of the study drug and have a Pregnancy test negative at screening and prior to randomization. Women who are not of childbearing potential are defined as women who have reached menopausal status (natural cessation of menstruation for ≥ 12 months and no other medical reasons); women who have undergone permanent sterilization (e.g., Salpingectomy, Bilateral oophorectomy, Hysterectomy); or women who have Congenital or acquired conditions that lead to infertility (e.g., Uterine hypoplasia, Turner's syndrome, Ovarian failure, as confirmed by gynecological experts). Male participants and female participants of childbearing potential must be willing to use highly effective contraceptive methods during the study period until 1 month after the last dose of the study drug and not donate sperm/eggs during the study period until 1 month after the last dose of the study drug.

You may not qualify if:

• Pregnant or lactating women.
• History of excessive smoking, alcoholism or Drug of Abuse within 6 months prior to screening. Alcoholism is defined as alcohol consumption of more than 14 units per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine); excessive smoking is defined as current average daily smoking of more than 10 cigarettes.
• In the opinion of the investigator, any other situation that may interfere with the participant's compliance and completion of the protocol, or affect the efficacy and safety evaluation of the study drug.
• Prior use of JT002 or a history of drug allergy to any study drug component is known. Drug allergy or hypersensitivity to immunosuppression/immunomodulators at screening will result in an unacceptable risk to participants if they participate in this study.
• Patients with rhinitis who have previously demonstrated an inability to tolerate nasal drops.
• Patients with perennial allergic rhinitis, unless the investigator evaluates that the patient's current symptoms and signs are caused by obvious exacerbation of seasonal allergic rhinitis.
• Nasal disorders that may affect drug absorption are found on nasal examination on screening day, such as nasal mucosal erosion, nasal mucosal ulcer, sinusitis, rhinitis.
• Medicamentosa, nasal polyps or abnormal nasal cavity structure, nasal trauma (such as nasal puncture), or septal deviation or nasal septum perforation.
• Patients who have received nasal operation within 3 months prior to screening or have incompletely healed nasal trauma.
• Active respiratory tract infection (including but not limited to Bronchitis, pneumonia or influenza, upper respiratory tract infection or Sinus infection) within 14 days prior to screening, or patients who may develop upper respiratory tract infection during the treatment run-in period. Occasional acute asthma or patients with mild exercise-induced asthma are acceptable, provided that the treatment is limited to inhaled short-acting β-agonists (maximum 8 times per day).
• Have a serious history of systemic infection or require hospitalization and/or intravenous anti-infective therapy (e.g., antibiotics, antifungal agents, antiviral agents) for ≥3 days within 12 weeks prior to screening.
• Patients with eye infections, e.g., ocular herpes simplex, Conjunctivitis infective (except Conjunctivitis associated with seasonal allergic rhinitis).
• Participants who plan to travel to areas outside their permanent residence (i.e., leaving the area of seasonal allergy exposure) for more than 2 consecutive days or more than 3 cumulative days (not consecutive) during the study period.
• History (at present) of immunodeficiency infection (e.g., Pneumocystis jirovecii pneumonia, Histoplasmosis, Coccidioidomycosis); or other known Immunodeficiency.
• History of lymphoid proliferative disease (current); or signs or symptoms of lymphoid proliferative disorder or any known neoplasm malignant, or history of or current neoplasm malignant (except completely resected and without evidence of recurrence squamous cell carcinoma of skin or basal cell carcinoma or cervix carcinoma in situ) within 5 years prior to screening.

Sponsors & Collaborators

• Shanghai JunTop Biosciences Co., LTD: lead

Study Sites (44)

Beijing Youan Hospital Capital Medical University

Beijing, Beijing Municipality, 100069, China

Location

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

Location

Fujian Medical University Union Hospital

Fuzhou, Fujian, 350001, China

Location

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, 350004, China

Location

Wuwei People's Hospital

Wuwei, Gansu, 733000, China

Location

Shenzhen Nanshan District People's Hospital

Shenzhen, Guangdong, 518000, China

Location

Shenzhen University General Hospital

Shenzhen, Guangdong, 518000, China

Location

Zhengzhou Central Hospital

Zhengzhou, Hanan, 450000, China

Location

The Second Hospital of Baoding City

Baoding, Hebei, 200131, China

Location

Cangzhou Central Hosptial

Cangzhou, Hebei, 061014, China

Location

Hebei Retro China Central Hosptial

Hebei, Hebei, 065000, China

Location

Hebei Provincial Hospital of Traditional Chinese Medicine

Shijiazhuang, Hebei, 050000, China

Location

The Third Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050051, China

Location

The First Affiliated Hospital of Hebei North University

Zhangjiakou, Hebei, 075061, China

Location

The People's Hospital of daqing

Daqing, Heilongjiang, 150081, China

Location

The Fourth Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, 150001, China

Location

Jingzhou Central Hospital (Jingzhou Hospital affiliated to Yangtze University)

Jingzhou, Hubei, 434000, China

Location

Wuhan Central Hospital

Wuhan, Hubei, 430014, China

Location

Renmin Hospital of Wuhan University

Wuhan, Hubei, 430060, China

Location

The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, 010030, China

Location

BaogangHospital of InnerMongolia

Baotou, InnerMongolia, 014010, China

Location

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 200000, China

Location

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China

Location

The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China

Location

Shengjing Hospital Affiliated to China Medical University

Shenyang, Liaoning, 110000, China

Location

Liaoning Provincial Health Industry Group Iron Coal General Hospital

Tieling, Liaoning, 112700, China

Location

Chifeng municipal hospital

Chifeng, Mongolia, 024099, China

Location

People's Hospital of Ningxia Hui Autonomous Region

Yinchuan, Ningxia, 750000, China

Location

The First People's Hospital of Yinchuan

Yinchuan, Ningxia, 750000, China

Location

Zibo central hospital

Zibo, Shandong, 255000, China

Location

Eye&Ent Hospital of fudan University

Shanghai, Shanghai Municipality, 200031, China

Location

Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center

Shanghai, Shanghai Municipality, 201399, China

Location

Heping hospital affiliated to Changzhi medical college

Changzhi, Shanxi, 046000, China

Location

Second hospital of Shanxi Medical University

Taiyuan, Shanxi, 030001, China

Location

First Hospital Of Shanxi Medical University

Taiyuan, Shanxi, 030012, China

Location

Shanxi Bethune hospital

Taiyuan, Shanxi, 030032, China

Location

The First Affiliated Hospital of Xi 'an Jiaotong University

Xi’an, Shanxi, 710000, China

Location

The Second Affiliated Hospital of Xi 'an Jiaotong University

Xi’an, Shanxi, 710000, China

Location

Xi'an DaXing Hospital

Xi’an, Shanxi, 710016, China

Location

Xi'an High tech Hospital

Xi’an, Shanxi, 710075, China

Location

Yuncheng Central Hospital

Yuncheng, Shanxi, 044000, China

Location

Panzhihua Hospital of Integrated Traditional Chinese and Western Medicine

Panzhihua, Sichuan, 617000, China

Location

Tianjin People's Hospital

Tianjin, Tianjin Municipality, 300121, China

Location

The First Affiliated Hospital of Xinjiang Medical Universit

Ürümqi, Xinjiang, 830054, China

Location

MeSH Terms

Conditions

Rhinitis, Allergic, Seasonal

Condition Hierarchy (Ancestors)

Rhinitis, Allergic; Rhinitis; Nose Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: the proportion of patients receiving 200 μg BID, 400 μg BID, 400 μg QD, 800 μg QD and placebo was 1:1:1:1:1

Study Record Dates

• First Submitted: February 19, 2025
• First Posted: March 6, 2025
• Study Start: February 24, 2025
• Primary Completion: May 6, 2025
• Study Completion: May 14, 2025
• Last Updated: June 11, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (44)